(Q37633543)

21 August 2017

1 reference

title

Pegvisomant: current and potential novel therapeutic applications (English)

1 reference

21 August 2017

Carlo L Acerini

3

0 references

David B. Dunger

object named as

David B Dunger

series ordinal

2

0 references

author name string

G N Ajay Thankamony

series ordinal

1

1 reference

PubMed ID

19916734

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Biological Therapy

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

1553-1563

1 reference

21 August 2017

12

1 reference

Basic physiology of the growth hormone/insulin-like growth factor axis

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The crystal structure of affinity-matured human growth hormone at 2 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Human growth hormone and extracellular domain of its receptor: crystal structure of the complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Model for growth hormone receptor activation based on subunit rotation within a receptor dimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Growth hormone receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Growth hormone excess and the development of growth hormone receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Growth hormone receptor antagonist improves insulin resistance in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Pegylation: a novel process for modifying pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Guidelines for acromegaly management: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Long-term experience of pegvisomant therapy as a treatment for acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The German ACROSTUDY: past and present

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Growth factors and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

ACROSTUDY: Status Update on 469 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Both insulin sensitivity and insulin clearance in children and young adults with Type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903449222

10.1517/14712590903449222

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19916734